Binding of Organic Acids to Surface Receptors of Lymphocytes as an Immunosuppressive Mechanism in Uremia
Some organic acids which inhibit binding of small ligands to plasma, so called protein binding inhibitors (PB-Ix), accumulate in body fluids of patients with renal failure. PB-Ix are believed to bind to sites on the surface of albumin and inhibit its detoxification, transport and reservoir functions1)2)3). They may play a wider toxic role, such as immunosuppression in uremic patients. PB-Ix have been shown to inhibit the mitogenic activity of lymphocytes4).
KeywordsQuinolinic Acid Mitogenic Activity Hippuric Acid Uremic Patient Normal Lymphocyte
Unable to display preview. Download preview PDF.
- 3).T. Sanaka, H. Kasai, Y. Kawashima, F. Takahashi, Y. Hayasaka, K. Ota and N. Sugino: Chemical identification of protein binding inhibitor in uremic patients. Japanese Journal of Kidney and Dialysis 14:75–81, 1983.Google Scholar
- 4).T. Sanaka, Y. Kawashima, F. Takahashi, etal: Suppressive effect of uremic protein binding inhibitor on cultivated lymphocytes. Japanese J Nephrology 15:1063–1069, 1983.Google Scholar
- 5).T. Sanaka: Protein binding inhibitor in uremia. Japanese J Circulation 17:400–409, 1985.Google Scholar
- 6).K. Koide, J. Touyama, N. Inoue, et al: Oral Adsorbent. Japanese J Clinician (Nihon Rinsyou in Japanese) 43:422–440, 1985.Google Scholar
- 7).Y. Kawashima, T. Sanaka, N. Sugino: Suppressive effect of quinolinic acid on bone marrow erythroid growth in uremia. Abstract of Symposium Uremic Toxin, Gent, 1986.Google Scholar
- 8).T. Sanaka and K. Ota: Lymphocyte blastformation in uremic patients.Japanese J Clin Immunol 8:881–887, 1976.Google Scholar